Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EK-12 vs Interferon Beta-1a in RRMS
NCT03283397Phase 3Terminated
- Sponsor
- Bosnalijek
- Start
- Mar 2019
- Primary completion
- Jul 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of tridecactide in relapsing-remitting multiple sclerosis (RRMS), sponsored by Bosnalijek. Started Mar 2019; status: terminated.
02
Drugs
tridecactide
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT03283397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03283397.